Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Targeting abnormal lung fluid metabolism could reduce COVID-19 deaths and ventilator use.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.

Men have higher COVID-19 mortality rates than women due to biological and lifestyle factors.

COVID-19 infection may cause significant hair loss, but full hair recovery is likely without special treatment.